Celgene to Acquire Receptos for $7.2B

July 15, 2015

Celgene Corp. announced it has signed an agreement to acquire Receptos. Under the terms of the merger, Celgene will pay $232 per share in cash, or a total of approximately $7.2 billion, net of cash acquired.

Celgene says the acquisition of Receptos significantly enhances its Inflammation & Immunology (I&I) portfolio, further diversifying its revenue beginning in 2019 and beyond, and builds upon Celgene's growing expertise in inflammatory bowel disease (IBD). The transaction adds Ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to Celgene's diverse pipeline of potential disease-altering medicines and investigational compounds.

Based on clinical studies, Ozanimod demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), including its cardiac, hepatotoxicity and lymphocyte recovery profile. The phase III TRUE NORTH trial in UC is currently underway with data expected in 2018. The phase III RADIANCE and SUNBEAM RMS trials are ongoing and data are expected in the first half of 2017 to support a RMS approval in 2018. Additionally, Ozanimod is positioned to potentially become the first S1P receptor modulator to be approved for IBD.

"The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas," said Bob Hugin, Chairman and Chief Executive Officer of Celgene. "This acquisition enhances our I&I portfolio and allows us to leverage the investments made in our global organization to accelerate our growth in the medium and long-term."

Read the full release